PomegraNovartis Stock Sinks 14% on del-Desiran Failure; Board Overhaul Demanded
Why did Novartis stock fall 14%?
Novartis (NVS) stock fell 14% to $137.70 on Tuesday, September 8, when the $12 billion Avidity drug del-desiran failed Phase 3, prompting Artisan Partners to demand a board overhaul and M&A committee.
Key numbers
| NVS single-day drop (NYSE, Sep 8) | -13.9%worst single session in 20+ years (per [2]; source [4] says worst since Mar 2020) |
|---|---|
| Market cap erased (Sep 8) | ~$30Bfrom pre-crash market cap ~$304B |
| Avidity Biosciences acquisition cost | $12.0Bclosed Feb 27, 2026 at $72.00/share |
| NVS year-to-date return (Sep 15) | +0.03%from ~+15% peak before crash week |
| Del-desiran pre-failure peak annual sales estimate | $3.1B/yrBarclays forecast, now scrapped (per [4]) |
| NVS 52-week price range | $121.57–$170.46current $138.71, down 18.7% from 52W high |
What happened
Novartis (NVS) stock fell 14% to $137.70 on Tuesday, September 8, when the $12 billion Avidity drug del-desiran failed Phase 3, prompting Artisan Partners to demand a board overhaul and M&A committee. Del-desiran — the centrepiece of Novartis's February 2026 Avidity Biosciences purchase — missed the primary endpoint in the HARBOR Phase 3 study for myotonic dystrophy type 1, a progressive muscle-wasting disease, showing no statistically meaningful improvement over placebo. The selloff was Novartis's worst single trading session in over 20 years, wiping nearly $30 billion in market value and erasing all of the stock's year-to-date gains in one day. Artisan Partners, one of Novartis's 20 largest shareholders, publicly called on Chairman Giovanni Caforio to rebuild the board with genuine deal-making expertise and create a dedicated acquisitions committee to scrutinise transactions before they are signed off.
Why it matters
Novartis is one of the world's largest drug companies, and when it spends $12 billion on an acquisition, ordinary investors and patients expect something to show for it. Del-desiran's failure raises serious questions about whether Novartis overpaid for Avidity and whether its board has the expertise to evaluate billion-dollar biotech bets in a highly competitive market. The collapse adds to a pattern of costly M&A disappointments — the 2024 MorphoSys deal was also written down months after closing — increasing pressure for structural governance reform. If Artisan Partners wins its push, the result could be a stricter filter on future acquisitions, changing how a global pharma giant navigates the next decade of looming patent expirations.
Who this affects
- MarketbearishHigh impact
- NVS holders lost ~$30B in one session; all 2026 gains wiped.
- CompanybearishHigh impact
- Novartis faces board shake-up pressure after $12B acquisition flops.
- CompetitorsmixedLow impact
- Rival neuromuscular biotechs may benefit from del-desiran's failure.
- IndustrybearishMedium impact
- Failed M&A may push pharma boards toward tighter deal oversight.
Novartis vs AstraZeneca, Roche
How we got here
Novartis announces $12B deal to acquire Avidity Biosciences for del-desiran.
Avidity acquisition closes at $72/share; del-desiran enters Novartis pipeline.
Heart drug pelacarsen fails Lp(a)HORIZON late-stage trial after market close.
Del-desiran fails HARBOR Phase 3; NVS -14%, worst day in 20+ years, $30B wiped.
Artisan Partners publicly calls for full board overhaul and dedicated M&A committee.
What to watch
- Novartis board and Chairman Caforio's formal response to Artisan Partners' demands.Q4 2026
- Novartis Q3 2026 earnings and any guidance revision or pipeline update.2026-10-27
- Whether other top-20 NVS shareholders publicly back Artisan's governance push.Q4 2026
Educational content only. Not investment advice.
More briefsAll briefs →
S&P 500 Falls 0.5% as Fed Hike Odds Hit 90% and Market Cap Tops 252% of GDP
Paul Tudor Jones says S&P 500 (SPX) at 252% of GDP will deliver negative decade returns as bonds test 5%.
Alphabet Stock Falls 1.6% as Zero-Click Searches Hit Record
Alphabet (GOOGL) stock falls as 68% of US searches now end without a click, squeezing search ad economics.
ARM Stock Falls 46% From Peak on Fed Rate-Hike Odds
Arm Holdings (ARM) shed 46% from its June peak as Fed hike odds hit 87%, threatening its 79x valuation.